Switch to:
More From Other Websites
Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine Aug 24 2016
Genmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma Aug 23 2016
Articles of Association for Genmab A/S Aug 18 2016
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their... Aug 18 2016
Graphics Chip Titan Registers Insider Selling; Four Other Companies with Fresh Insider Buying Aug 18 2016
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in... Aug 17 2016
GENCOR INDUSTRIES INC Financials Aug 17 2016
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their... Aug 17 2016
Capital Increase in Genmab as a Result of Employee Warrant Exercise Aug 17 2016
ETF’s with exposure to Gencor Industries, Inc. : August 16, 2016 Aug 16 2016
Gencor Industries, Inc. :GENC-US: Earnings Analysis: Q3, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Genmab Enters Commercial License Agreement with Gilead for DuoBody® Technology Aug 10 2016
Genmab Announces Financial Results for the First Half of 2016 and Improves 2016 Financial Guidance Aug 09 2016
Gencor posts 3Q profit Aug 09 2016
Gencor posts 3Q profit Aug 09 2016
GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 09 2016
Gencor Releases Third Quarter Fiscal 2016 Results Aug 09 2016
Genmab Appoints Board Observer Aug 03 2016
Daratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in... Jul 25 2016
ETF’s with exposure to Gencor Industries, Inc. : July 18, 2016 Jul 18 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK